on September 22, 2005
Published online before print September 22, 2005, doi: 10.1161/01.ATV.0000187463.91403.b2
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on April 18, 2005
Accepted on August 7, 2005
Positive-Feedback Mechanisms of Coagulation. Their Role in Threshold Regulation
Jolyon Jesty * and Edward Beltrami
From the Division of Hematology, Health Sciences Center (J.J.), and the Department of Applied Mathematics and Statistics (E.B.), Stony Brook University, Stony Brook, NY.
* To whom correspondence should be addressed. E-mail: jolyon.jesty{at}sunysb.edu.
Abstract--Tissue factor (TF), the initiator of coagulation, continuously circulates in the plasma, and the clotting system "idles," generating very low levels of active clotting enzymes, clotting products, and by-products. Given the enormous amplification potential of the clotting cascade, rigorous control is required to ensure that such low-level stimulation does not cause massive system amplification and response. We propose that among the various mechanisms of regulation, activation thresholds may play a major role. These arise when positive-feedback reactions, of which there are several in the clotting system, are regulated by inhibitors. Such thresholds act like switches, so that small stimuli and/or nonproductive local conditions will generate no response, whereas larger stimuli or the existence of local prothrombotic conditions will produce a full, explosive response. We review here the evidence for system idling, the structures of the various feedback mechanisms of clotting, the mechanisms by which they can produce threshold behavior, and the possible role of thresholds in system regulation.
This article has been cited by other articles:
 |
|
 |
|
  N. Mackman The Role of Tissue Factor and Factor VIIa in Hemostasis Anesth. Analg., May 1, 2009; 108(5): 1447 - 1452. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Orfeo, K. E. Brummel-Ziedins, M. Gissel, S. Butenas, and K. G. Mann The Nature of the Stable Blood Clot Procoagulant Activities J. Biol. Chem., April 11, 2008; 283(15): 9776 - 9786. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. A. Tanaka, T. Taketomi, F. Szlam, A. Calatzis, and J. H. Levy Improved Clot Formation by Combined Administration of Activated Factor VII (NovoSeven(R)) and Fibrinogen (Haemocomplettan(R) P) Anesth. Analg., March 1, 2008; 106(3): 732 - 738. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Schneider and B. E. Sobel Conundrums in the Combined Use of Anticoagulants and Antiplatelet Drugs Circulation, July 17, 2007; 116(3): 305 - 315. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Ayala, D. J. Warejcka, M. Olague-Marchan, and S. S. Twining Corneal Activation of Prothrombin to Form Thrombin, Independent of Vascular Injury Invest. Ophthalmol. Vis. Sci., January 1, 2007; 48(1): 134 - 143. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Patel, L. R. Berry, and A. K.C. Chan Analysis of Inhibition Rate Enhancement by Covalent Linkage of Antithrombin to Heparin as a Potential Predictor of Reaction Mechanism J. Biochem., January 1, 2007; 141(1): 25 - 35. [Abstract] [Full Text] [PDF]
|
|